Communications in Prolactin Research (CPR) is a new, international, peer-reviewed, open access biomedical specialty journal devoted to publishing articles and scientific communications concerning the hormone prolactin. The following article types are considered: original research articles, rapid communications, review articles, case reports, data reports, field communications, letters to the editor, conference abstracts and reports, as well as special articles commissioned or written by the Editor-in-Chief. Articles published in CPR are distributed under the terms of the Creative Commons Attribution Licence (CC BY).  Indexing in the Directory of Open Access Journals (DOAJ) and Pubmed Central is scheduled.

CPR publishes articles concerning the hormone prolactin. All submissions relating to the biomedical exploration of prolactin, either directly or indirectly, are welcome. This includes work in which prolactin is the main focus of the investigation, as well as work in which prolactin is addressed together with other hormones or factors. The submission of clinical, translational, and experimental biomedical research is encouraged. Not within the scope of CPR is veterinary research, as well as experimental research with no biomedical or clinical significance. CPR is a publication by Yellow Thistle Publishing LTD (Covent Garden, London, UK) and lead by Editor-in-Chief Jakob Triebel MD (Nuremberg, Germany), a leading expert on prolactin (ORCID: https://orcid.org/0000-0002-1989-8645).

For authors: why submit to CPR?

CPR is the first and only biomedical specialty journal focussed entirely on publishing research on the hormone prolactin. It is aimed to establish itself as the leading, authoritative source for publications in prolactin research. CPR is an entirely open-access journal and as such supports the free global distribution of research results and communication within this specialty.

After successful evaluation of submitted manuscripts, authors receive a peer-reviewed, professionally edited and formatted article, fully citable and distributed under the Creative Commons Attribution Licence (CC BY). This means that the copyright is retained by the authors, and that the article can be distributed freely as long as the original source is stated. Provided by Crossref, all articles published in CPR receive a DOI (digital object identifier) and a set of metadata to ensure discoverability and optimal indexing. CPR is employing Janeway Systems hosting which ensures the safe, reliable and smooth operability of the journal.

Article evaluation, editorial workflow, and journal policies

All submissions are initially evaluated by the Editor-in-Chief for their suitability to enter peer-review. Manuscripts may be rejected at this point. Manuscripts undergo screening for plagiarism and research integrity. Duplicate (parallel) submissions are forbidden. Language-editing may be requested from the authors or initiated by the Editor. CPR employs a double-blind peer-review system for the evaluation of submitted manuscripts. The names and affiliations of the reviewers will be indicated on the title page of accepted and published manuscripts. The reviewers identity remains anonymous in case of manuscript rejections. Reviewers for CPR receive a financial compensation for evaluated manuscripts, irrespective of whether they recommend publication or rejection of a manuscript. CPR is aiming to establish an international editorial board. CPR will also request ad hoc specialty editors as needed. An annual journal report will be published, reporting relevant journal metrics.
CPR generally adopts and complies with the 2025 International Committee of Medical Journal Editors (ICMJE) recommendations for conduct, reporting, editing, and publication of scholarly work in medical journals. ICMJE Recommendations

Browse through the submission page for more information: submission page

 

Publishing Policy

1. Purpose & Scope

CPR publishes articles concerning the hormone prolactin. All submissions relating to the biomedical exploration of prolactin, either directly or indirectly, are welcome. This includes work in which prolactin is the main focus of the investigation, as well as work in which prolactin is addressed together with other hormones or factors. The submission of clinical, translational, and experimental biomedical research is encouraged. Not within the scope of CPR is veterinary research, as well as experimental research with no biomedical or clinical significance. Submissions must make a clear contribution to the field and may not contain previously published results without proper attribution.

2. Submission & Format

Online submission through the CPR manuscript portal.
Manuscripts are accepted in Microsoft Word format
All figures, tables, and supplementary material must be provided in high‑resolution quality.

3. Open Access & Licensing

All articles are published under the Creative Commons Attribution 4.0 International (CC‑BY 4.0) licence.
For authors unable to pay the Article Processing Charge (APC), waiver options are available on a case‑by‑case basis.

4. Data & Material Availability

Raw data, code, and any other research materials necessary for reproducibility must be publicly accessible (e.g., via Zenodo, Figshare, GitHub) unless ethical or legal restrictions apply.

5. Peer‑Review Process

All submissions are initially evaluated by the Editor-in-Chief for their suitability to enter peer-review. Manuscripts may be rejected at this point. Manuscripts undergo screening for plagiarism and research integrity. Duplicate (parallel) submissions are forbidden. Language-editing may be requested from the authors or initiated by the Editor. CPR employs a double-blind peer-review system for the evaluation of submitted manuscripts. The names and affiliations of the reviewers will be indicated on the title page of accepted and published manuscripts. The reviewers identity remains anonymous in case of manuscript rejections. Reviewers for CPR receive a financial compensation for evaluated manuscripts, irrespective of whether they recommend publication or rejection of a manuscript.The names and affiliations of the reviewers will appear on the first page of accepted and published papers. Reviewer identities remain anonymous in case of rejections. 

6. Ethics & Integrity

All studies must have ethical approval (e.g., Institutional Review Board) and adhere to the Declaration of Helsinki or equivalent guidelines.
Conflict‑of‑Interest statements are mandatory for authors, reviewers, and editors.
Plagiarism, data fabrication, and inappropriate image manipulation result in immediate rejection and notification of the authors’ institutions.

7. Corrections, Retractions & Comments

Errata and corrigenda are published as separate, linked documents.
Retractions are issued after thorough investigation and are clearly marked.

• A retraction will be issued where a major error (e.g., in the methods or analysis) invalidates the conclusions in the article, or where it appears research or publication misconduct has taken place (e.g., research without required ethical approvals, fabricated data, manipulated images, plagiarism, duplicate publication, etc.). The decision will follow a full investigation by our editorial staff. Authors and institutions may request a retraction of their articles if they believe their reasons meet the criteria for retraction. 

Retraction will be considered in cases where:

• There is clear evidence that the findings are unreliable, either as a result of misconduct (e.g., data fabrication or image manipulation) or honest error (e.g., miscalculation or experimental error).
  The findings have previously been published elsewhere without proper referencing, permission, or justification (e.g., cases of redundant or duplicate publication).
  The research constitutes plagiarism.
  There is evidence or concerns of authorship for sale.
  Citation manipulation is evident within the published paper.
  There is evidence of compromised peer review or systematic manipulation.
  There is evidence of unethical research, or there is evidence of a breach of editorial policies.
  The authors have deliberately submitted fraudulent or inaccurate information.

8. Author Rights & Responsibilities

Authors retain copyright but grant the journal unrestricted rights to reproduce and distribute the work under CC‑BY 4.0.
Each author is responsible for the accuracy of his/her contributions and must ensure the overall integrity of the manuscript.

9. Licence & Fee Information

Article Processing Charge (APC):

• Original Research: 1200 €
• Review: 1200 €
• Rapid Communication: 850 €
• Case Report: 850 €
• Data Report: 450 € 
• Field Communication: 450 €
• Conference Communication: 250 €
• Letter to the Editor: 250 €
• Special Articles: commissioned by the Editor - no APC
• Discounts available for early‑career researchers, students, and institutions from low‑income countries.

Payment details will be provided after manuscript acceptance.

10. Contact & Complaints

Questions about the policy, submissions, or ethical concerns should be directed to the Editor-in-Chief: eic_cpr@protonmail.com.
Complaints regarding the review process or possible policy violations are examined.

11. About the publisher

CPR is published by Yellow Thistle Publishing LTD, Registered Office and Business Address: 71-75 Shelton Street, Covent Garden, London, United Kingdom, WC2H 9JQ, web: Yellow Thistle Publishing LTD